|March 2002 (Volume 9, Issue 3)
Article 257: Top AHCs Turn Away from Industry-Sponsored Trials
- Centralized clinical trial offices at select academic health centers are consolidating in the wake of a renewed commitment to conduct basic and translational research. This consolidation may drive growth for independent investigative sites and AHCs pursuing industry-sponsored clinical trials.
Article 258: Sponsors Take on Patient Recruitment
Article 259: CentreStage Europe: A Guide to Conferences in Europe
- The majority of top pharmaceutical companies have now established centralized patient-recruitment functions. These functions provide a variety of support services designed to address inefficiencies throughout the clinical trial process.
Article 260: Eye On: Colorectal Cancer
- It ’s conference season once again in Europe.Seve al conference organizers have noted an increased interest from Americans who wish to present at the European conferences,seeing additional opportunities to gain exposure for their companies and products.
- Colon cancer is the second most common cause of cancer death today. One hundred and fifty thousand new cases of colon cancer are diagnosed every year.In addition to ever-improving screening and detection modalities, there are many areas of colorectal cancer drug development underway. CenterWatch Drug Intelligence has identified a total of 42 drugs in the pipeline.